The development of methods for the nucleophilic radiofluorination of electron-rich (hetero)arene precursors represents a long-standing challenge for the radiochemistry community.^[@ref1]−[@ref3]^ Most existing routes to ^18^F-labeled electron-rich aromatics are limited by the requirement for prefunctionalization of the labeling site with, for example, a boron, tin, hypervalent iodine, or transition-metal substituent.^[@ref3],[@ref4]^ These prefunctionalized precursors are often not commercially available and must be accessed via multistep synthesis and purification sequences.^[@cit3a]−[@cit3c],[@cit3e]−[@cit3k]^ Furthermore, a number of radiofluorination precursors (e.g., hypervalent iodine reagents and Ni/Pd complexes) have limited shelf lives, which precludes widespread clinical applications.^[@ref5]^ Overall, methods for the direct nucleophilic radiofluorination of arene C--H bonds would help to address these challenges.^[@ref6]^

Several methods have been reported for the *electrophilic* C--H radiofluorination of electron-rich arenes ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}A).^[@cit1c],[@cit1f]^ These involve the initial generation of an ^18^F^+^ source (e.g., \[^18^F\]F~2~ or \[^18^F\]Selectfluor) and subsequent electrophilic aromatic substitution (S~E~Ar) between the ^18^F^+^ reagent and the arene substrate. This approach eliminates the need for prefunctionalization. However, the requirement for ^18^F^+^ reagents leads to three key limitations. First, ^18^F^+^ reagents afford radiofluorinated products with low specific activity due to the need to use carrier \[^19^F\]F~2~ gas for their synthesis.^[@ref7]^ Second, the production of ^18^F^+^ sources requires specialized facilities.^[@ref8]^ Third, the high reactivity of electrophilic fluorinating reagents often results in poor site and chemoselectivity.^[@ref9]^
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These limitations could be addressed through the development of a nucleophilic radiofluorination of (hetero)aryl C--H bonds ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}B), as this would enable the use of easily accessible bench-stable precursors in combination with high specific activity \[^18^F\]KF. The key challenge for this approach is the electronic mismatch between nucleophilic \[^18^F\]KF and the nucleophilic electron-rich arene substrate (Ar--H). We hypothesized that this could be overcome via an umpolung strategy that would invert the polarity of the arene substrate ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}C). Specifically, an initial S~E~Ar reaction with an electrophile (E^+^) would functionalize the C--H bond and generate an electrophilic coupling partner (Ar--E).^[@ref10]^ Ar--E could then undergo in situ nucleophilic radiofluorination with \[^18^F\]KF. We demonstrate herein the realization of this approach using I^III^-based electrophiles. This enables the selective radiofluorination of electron-rich aromatics, including toluene, anisole, aniline, pyrrole, and thiophene derivatives. Furthermore, it can be scaled to automated radiosynthesis modules and used to access high specific activity ^18^F-labeled products.

The approach in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}C is predicated on the identification of an electrophile (E^+^) that (i) undergoes site-selective S~E~Ar with diverse electron-rich (hetero)arenes and (ii) generates an intermediate (Ar--E) that can participate in a nucleophilic radiofluorination. Notably, it is not critical that Ar--E be stable; indeed, a key advantage of this approach is that Ar--E will be used in situ, thus precluding the need for isolation/storage of this intermediate. On the basis of these considerations, we selected I^III^ reagents as E^+^. As shown in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}, ArI^III^X~2~ salts are known to participate in site-selective S~E~Ar reactions with electron-rich (hetero)arenes.^[@ref11]−[@ref13]^ Furthermore, these transformations yield diaryliodonium salts, which we have shown to undergo Cu-catalyzed radiofluorination with \[^18^F\]KF.^[@cit3a],[@ref14]^ While electron-rich diaryliodonium salts are notoriously unstable,^[@cit5a],[@ref15]^ this approach offers the advantage that they are generated in situ from stable and readily available C--H starting materials.
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Our initial investigations focused on the reaction of anisole (**1a**) with MesI(OH)OTs ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). These partners were selected because they are well-known to undergo S~E~Ar in the presence of Lewis or Brønsted acid activators^[@ref16]^ (**MY** or **HY**, respectively, in [eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}) to form a single isomeric product, \[4-MeOC~6~H~4~-I-Mes\]^+^ (**2a**). Furthermore, **2a** is known to undergo Cu-catalyzed radiofluorination with \[^18^F\]KF.^[@cit3a],[@ref13],[@ref14],[@ref17]^ There were two key considerations for our choice of aryliodonium electrophile and activator for this one-pot radiofluorination. First, these reagents should not contain nucleophilic counterions (**Y**) (e.g., carboxylates), as these are susceptible to undesired coupling reactions with the diaryliodonium intermediate **2** ([eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}).^[@ref18]^ Second, their byproducts should be compatible with the Cu-mediated radiofluorination step.

###### Optimization of the Radiofluorination of Anisole[a](#t1fn1){ref-type="table-fn"}
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  entry                                                                activator    base                    RCC **3a**[b](#t1fn2){ref-type="table-fn"} (%)
  -------------------------------------------------------------------- ------------ ----------------------- ------------------------------------------------
  1                                                                    TsOH·H~2~O                           27 ± 4 (*n* = 4)
  2                                                                    TsOH·H~2~O   *i*Pr~2~NEt (20 μmol)   61 ± 8 (*n* = 9)
  3                                                                    TMSOTf                               5 ± 2 (*n* = 5)
  4                                                                    TMSOTf       *i*Pr~2~NEt (10 μmol)   58 ± 0.4 (*n* = 3)
  5                                                                    TMSOTf       *i*Pr~2~NEt (20 μmol)   78 ± 4 (*n* = 3)
  6[c](#t1fn3){ref-type="table-fn"},[d](#t1fn4){ref-type="table-fn"}   TMSOTf       *i*Pr~2~NEt (20 μmol)   87 ± 4 (*n* = 13)

Conditions: (1) **1a** (10 μmol), MesI(OH)OTs (10 μmol), activator (10 μmol), CH~2~Cl~2~ (40 μL); (2) (MeCN)~4~CuOTf (10 μmol), \[^18^F\]KF·18-crown-6·K~2~CO~3~ complex in DMF (100 μL, 80--1200 μCi), total volume 1.0 mL.

RCC was determined by radio-TLC (average of *n* runs). The identity of **3a** was confirmed by HPLC.

Quinaldic acid (10 μmol) was included in step 2.

98:2 selectivity (**3a**/\[^18^F\]fluoromesitylene) detected by radio-HPLC.

With these criteria in mind, we first examined the use of TsOH as the activator. The two-step procedure involved (1) stirring **1a**, MesI(OH)OTs, and TsOH (10 μmol) in CH~2~Cl~2~ for 18 h at 25 °C and then (2) adding the reaction mixture to a solution of (MeCN)~4~CuOTf and \[^18^F\]KF·18-crown-6 in DMF and heating at 85 °C for 20 min. The reactions were assayed using radio-TLC and radio-HPLC, and these initial conditions afforded a 27% radiochemical conversion (RCC) to 4-\[^18^F\]fluoroanisole (**3a**) ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1).^[@cit3a]^ We hypothesized that the addition of a base in step 2 would quench the residual acid from the diaryliodonium formation step. This was expected to enhance the radiofluorination yield, as Cu-catalyzed nucleophilic fluorinations are known to be acid-sensitive.^[@ref19]^ Indeed, a screen of bases revealed that ^*i*^Pr~2~NEt (20 μmol) increased the RCC to 61 ± 8% (*n* = 9, entry 2).^[@ref20],[@ref21]^

Trimethylsilyl trifluoromethanesulfonate (TMSOTf) also proved to be an effective activator for the S~E~Ar reaction. The use of this activator in step 1 coupled with ^*i*^Pr~2~NEt (20 μmol) in step 2 delivered 4-\[^18^F\]fluoroanisole (**3a**) in 78 ± 4% RCC (*n* = 3, entry 5). Finally, the evaluation of different additives revealed that the addition of quinaldic acid (10 μmol) to the Cu-mediated radiofluorination under otherwise identical conditions resulted in a RCC of 87 ± 4% (*n* = 13, entry 6).^[@ref22]^ Notably, the RCC of this transformation of **1a** to **3a** (87%) is comparable to that reported using isolated \[4-MeOC~6~H~4~-I-Mes\]^+^ as the substrate for Cu-catalyzed radiofluorination (79%).^[@cit3a]^

The site-selectivity of the reaction of anisole was determined by radio-HPLC analysis^[@ref23]^ via comparison to authentic standards of the three possible isomers (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.orglett.7b01902/suppl_file/ol7b01902_si_001.pdf) for complete details). The ^18^F-fluorination proceeded to afford the *para*-isomer with \>99:1 selectivity.^[@ref12],[@cit13a]−[@cit13d]^ This high selectivity is fully consistent with that reported for S~E~Ar reactions between hypervalent iodine reagents and related electron-rich arene substrates.^[@ref12]^ Importantly, \<2% of \[^18^F\]fluoromesitylene was detected under any of the conditions examined.

We next evaluated the scope of this C--H radiofluorination ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref24]^ A series of anisoles (**3a**--**f**), protected anilines (**3g**--**i**), and toluene (**3j**,**k**) derivatives reacted under the standard conditions to form ^18^F-labeled arenes in \>80% RCC. The transformation was tolerant of aryl halides (**3c** and **3o**), esters and tertiary amides (**3d**, **3g**, and **3m**), sulfonamides (**3h**, **3o**, and **3q**), and nitro groups (**3q**) as well as substitution adjacent to the site of fluorination (**3e**). Protic functional groups (e.g., alcohols, amines, and amides) were not compatible and were thus protected prior to the reaction.^[@ref27]^ The radiofluorination of heterocycles, including thiophene, pyrrole, and uracil, required elevated temperature (105 °C) to afford **3l**--**n**. Notably, the radiofluorination of these heterocycles proceeded with lower selectivity, and significant quantities of \[^18^F\]fluoromesitylene were observed in these systems. However, in all cases, this byproduct was readily separable by HPLC.^[@ref25],[@ref26]^ The formation of 2-\[^18^F\]fluoro-3-methylthiophene (**3l**) in 25% RCC is particularly noteworthy, as thiophenes are particularly challenging to radiofluorinate using other methods.^[@cit1d]−[@cit1f],[@ref28]^ Indeed, thiophene is typically used as the inert ligand on diaryliodonium salts to direct radiofluorination to the other arene ligand.^[@cit1d]−[@cit1f],[@ref29]^
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We next examined the late-stage C--H radiofluorination of fragments that appear in pharmaceuticals. In one example, the dibenzothiazepine fragment of tianeptine (Coaxil), underwent radiofluorination to yield **3o** in 18% RCC. Additionally, both *O*-Bn-protected propofol (an anesthetic and sedative) and *N*-Bn-protected nimesulide (a nonsteroidal anti-inflammatory) reacted under our standard conditions to yield ^18^F-analogues **3p** and **3q** in 87% and 81% RCC, respectively.

A final set of experiments focused on automation of this reaction on a TRACERLab FX~FN~ radiosynthesis module used for the preparation of clinical radiotracers.^[@cit2b]^ Initial automated studies were conducted for anisole (**1a**) using ∼1.5 Ci of \[^18^F\]fluoride (\[^18^F\]KF·18-crown-6·KOTf) and afforded 4-\[^18^F\]fluoroanisole (**3a**) in 56 ± 4% RCC and a specific activity of 2700 ± 1900 Ci/mmol (*n* = 4).^[@ref20],[@ref30]^ We also automated the radiofluorination of *N*-Bn-protected nimesulide without any further optimization. Radiolabeling was conducted using ∼1.5 Ci of \[^18^F\]fluoride, and the product was purified via semipreparative HPLC to yield a formulated 41 ± 31 mCi dose of **3q** in 2.8 ± 1.9% non-decay-corrected radiochemical yield (RCY) with 2800 ± 700 Ci/mmol specific activity (*n* = 3, [eq [2](#eq2){ref-type="disp-formula"}](#eq2){ref-type="disp-formula"}). This proof-of-concept demonstration provides a foundation for the application of this method to the synthesis of other radiotracer targets.

In summary, this report describes a method for the nucleophilic radiofluorination of electron-rich arene C--H bonds that enables the late-stage C--H functionalization of (hetero)aromatic scaffolds. This approach eliminates the need to isolate/store prefunctionalized starting materials, instead leveraging the bench stability and availability of electron-rich aromatic substrates. Current efforts are focused on the application of this C(sp^2^)--H to C--^18^F radiofluorination chemistry to clinically relevant targets.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acs.orglett.7b01902](http://pubs.acs.org/doi/abs/10.1021/acs.orglett.7b01902).Experimental and spectral data for all new compounds and all reactions ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.orglett.7b01902/suppl_file/ol7b01902_si_001.pdf))
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